Abstract Library

#2287 Mitochondrial or Aerobic Glycolysis Oriented Metabolism May Define Pancreatic Neuroendocrine Tumors (PanNET) Resistance to mTOR-Targeting Therapies

Introduction: The mTOR inhibitor Everolimus is approved for the treatment of PanNET and no predictive biomarker is available. mTOR is a central node controlling mitochondrial and aerobic glycolytic metabolisms.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cros J, Bucau M, Raffenne J, Soukeur M, Dumont F,

Keywords: mTOR, everolimus, pancreatic NET, metabolism,

#945 Interference of Nutrient/Oxygen Availability with mTOR Activation and Inhibition in Lung Carcinoids: A Tissue and Cellular Study

Introduction: MTOR is capable of coupling cellular nutrient sensing to metabolic homeostasis. However, little is known of the interactions between cancer‐specific metabolic pathways and profiles of responsiveness to mTOR inhibition in neuroendocrine tumors.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Volante M

Authors: Rapa I, Giorcelli J, Votta A, Marino G, Righi L,

Keywords: lung, carcinoid, mTOR, metabolic pathway,